In this issue:
Novel approaches in improving PFS of high risk MM patients.
Health-related quality of life outcomes in RRMM
The impact of age and updated outcomes from the FIRST trial
Subcutaneous bortezomib – comparison of clinical or home administrations
Unrelated cord blood transplantation in MM
MRD-negative status and superior survival outcomes – meta-analysis
Oral ixazomib and several renal dysfunction – evaluating the single-dose pharmacokinetics
Could statins reduce mortality and improve bone formation in MM?
Preclinical data for the development of MCL1 inhibitors
First reported genome-wide association study for bortezomib-induced peripheral neuropathy
Please login below to download this issue (PDF)